CurrentmhnPolicy HNCA.CP.MP.65

Clinical Policy: Prolotherapy

This policy governs coverage determination for prolotherapy (intraligamentous or periarticular injection of proliferative/sclerosing solutions) for treatment of musculoskeletal pain for Health Net of California members.

Policy Summary

Payermhn

PolicyClinical Policy: Prolotherapy

Policy CodePolicy HNCA.CP.MP.65

Change TypeNo material change

Effective DateJun 25, 2023

Next Review Date

Key ActionVerify plan-specific prior authorization requirements for HCPCS code M0076 when submitting claims for prolotherapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

insufficientevidence to support efficacy

4 trialsRCTs identified

M0076HCPCS referenced

Coverage Determination

Not Medically Necessary / Insufficient Evidence

Not covered due to insufficient evidence

Overall stance: Prolotherapy is considered to have insufficient evidence to support efficacy for musculoskeletal pain or any other indication and is therefore not supported as medically necessary.

Policy statement found in document.

It is the policy of Health Net of California that there is insufficient evidence to support the efficacy of prolotherapy for musculoskeletal pain or any other indication.

Although prolotherapy has been evaluated in the literature, available randomized placebo-controlled trials are few and have methodological limitations (including problems with blinding) and have not consistently demonstrated improvement in pain or function. Therefore current evidence is insufficient to show meaningful improvement in health outcomes and does not support routine use of prolotherapy.

Coding

Referenced HCPCS CodesHCPCS

M0076

Prolotherapy

Policy Summary

Payermhn

PolicyClinical Policy: Prolotherapy

Policy CodePolicy HNCA.CP.MP.65

Change TypeNo material change

Effective DateJun 25, 2023

Next Review Date

Key ActionVerify plan-specific prior authorization requirements for HCPCS code M0076 when submitting claims for prolotherapy.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions & Billing Notes

Prior Authorization

Prior Authorization Required

Prior authorization requirements vary by plan. Verify whether prior authorization is required for prolotherapy services (HCPCS code M0076) with the member's specific Health Net plan before scheduling or billing.

HCPCS: M0076 (Prolotherapy) — check plan-specific prior authorization

Documentation Required

Coding & Documentation Guidance

Providers should document clinical rationale, prior conservative therapies tried, treatment site(s), number of injection sessions, and substance(s) injected. Reference current CPT and HCPCS coding guidance and include supporting medical record documentation when submitting claims to reduce risk of administrative denial.

Document: indication, prior conservative care, treatment dates, injected substance, body site, number of sessions

Denial Risk

Denial Risk — Insufficient Evidence

Prolotherapy is considered not medically necessary per this policy due to insufficient evidence of efficacy for musculoskeletal pain or other indications. Claims for prolotherapy (e.g., HCPCS M0076) may be denied on the basis of lack of medical necessity.

Denial risk for insufficient clinical evidence
Affected code: HCPCS M0076 (Prolotherapy)

Billing Rule

Billing/Coding Reminder

Coding note: this policy references CPT and HCPCS codes for informational purposes only; inclusion does not guarantee coverage. Providers must use the most up-to-date coding manuals and payer-specific billing rules when submitting claims.

HCPCS: M0076 — listed as Prolotherapy
Verify current CPT/HCPCS code descriptions before billing

Background

Prolotherapy involves injection of proliferative or sclerosing agents (examples reported include zinc sulfate, psyllium seed oil, combinations of dextrose, glycerine and phenol, or dextrose alone) into torn or stretched ligaments, tendons, or periarticular tissues to provoke an inflammatory response and promote tissue repair. Treatments may be a single injection or a series of injections and are often diluted with a local anesthetic.

Definitions

Prolotherapy definition

TermProlotherapy

DefinitionInjection of sugar- or saline-based proliferative/sclerosing solutions into affected ligaments, tendons, or periarticular tissues to stimulate an inflammatory healing response and promote tissue repair.

Common agentsZinc sulfate, dextrose (alone or with glycerine and phenol), psyllium seed oil; often diluted with local anesthetic.

Target tissuesTorn or stretched ligaments, tendons, and periarticular tissues.

Intended effectPromote tissue repair/growth by prompting release or enhanced activity of growth factors (e.g., cytokines).

Conservative Treatment Requirements

Frequency Limits

Prolotherapy frequency limits

Frequency limit statementNo frequency limits specified in this policy document for prolotherapy.

Injection seriesPolicy notes prolotherapy may involve a single injection or a series of injections, but provides no numeric limits or intervals.

Imaging requirementNo imaging requirements specified in relation to frequency or administration.

Imaging Requirements

Note

Imaging: no imaging required

No imaging requirements are specified in the policy for prolotherapy; imaging is not listed as a prerequisite for coverage evaluation.

Policy notes no imaging requirements for prolotherapy
Do not rely on imaging as a stated coverage requirement in claims

Not Covered

Prolotherapy is not covered for treatment of musculoskeletal pain or any other indication because current evidence is insufficient to support its efficacy or to demonstrate meaningful improvement in pain, function, or quality of life.